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A B S T R A C T
Inpatient diabetes is a common medical problem encountered in up to 25–30% of hospitalized patients.
Several prospective trials showed beneﬁts of structured insulin therapy in managing inpatient hyper-
glycemia albeit in the expense of high hypoglycemia risk. These approaches, however, remain underutilized
in hospital practice. In this review, we discuss clinical applications and limitations of current therapeu-
tic strategies. Considerations for glycemic strategies in special clinical populations are also discussed. We
suggest that given the complexity of inpatient glycemic control factors, the “one size ﬁts all” approach
should bemodiﬁed to safe and less complex patient-centered evidence-based treatment strategies without
compromising the treatment eﬃcacy.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
About 25–30% of hospitalized patients have a known diagnosis
of diabetes while additional 5–10% of patients will have the diag-
nosis discovered during admission for the ﬁrst time [1–4]. Over the
last decade, the inpatient diabetes prevalence remains steady as was
reported by the same group of authors in 2002 and 2016 [3,5]. The
Endocrine Society clinical practice guidelines suggest that, based
on retrospective and observational evidence, inpatient random blood
glucose (BG) levels below 180mg/dL and fasting BG below 140mg/dL
are more likely to be associated with better clinical outcomes such
as reduced risk of infections, less disability after hospital dis-
charge, and improved perioperative complications in non-critically
ill medical and surgical patients [1]. However, in prospective trials,
the positive impact of BG goal-driven glycemic control in non-
intensive care unit (non-ICU) setting was less evident [6] raising a
question if intensive management of hyperglycemia in non-ICU
setting is of targetable clinical beneﬁt. Only one randomized con-
trolled trial conducted in surgical patients on the ﬂoor showed that
scheduled insulin therapy targeting recommended inpatient gly-
cemic goals reduces incidence of infections and combined post-
operative complication rate [7]. Interventional studies in medical
patients with diabetes could not reproduce similar beneﬁts [6]. It
is important to recognize that to date there are no prospective trials
that tested clinical eﬃcacy and outcomes of targeting different
inpatient BG goals in non-critically ill patients.
Insulin therapy is suggested as cornerstone treatment strategy
in the management of inpatient diabetes [1,8]. Over the last 20 years
of intensive clinical research, wewitnessed a remarkable move away
from the old approach of using insulin per “sliding scale” due to its
poor glycemic eﬃcacy and potential harms in the management of
inpatient diabetes [9,10]. However, with the evolution of evidence
supporting anti-hyperglycemic eﬃcacy of basal-bolus insulin (BBI),
high rates of hypoglycemia were reported suggesting that even in
the hands of experienced endocrinologists conducting these trials,
new insulin strategies may not be as harmless as originally thought
[7,11–14]. While the clinical beneﬁts from achieving proposed gly-
cemic goals in non-critically ill patients with diabetes are yet to be
determined at least in medical patients, insulin-induced hypogly-
cemia appears to be more of a concern during inpatient diabetes
management [15]. Therefore, newer strategies utilizing non-
insulin approaches in the management of inpatient hyperglycemia
were proposed and recently studied in hospitalized patients with
diabetes [16,17].
In addition to the risk of hypoglycemia due to intensive inpa-
tient insulin regimens, some other factors may lessen current
enthusiasm in the ﬁeld and, most importantly, uptake of current
anti-hyperglycemic strategies bynon-endocrinologists. System-based
issues, provider-related factors, and patient-speciﬁc presentation all
cause unavoidable confusion among the hospital administrators and
non-endocrinology providers in regard to howhyperglycemia should
be managed in the non-ICU setting. In Fig. 1, we combined poten-
tial contributors to the low adherence to current glycemic
management recommendations. Of note, it is very diﬃcult to enforce
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hospital administration to implementhyperglycemia treatment strat-
egies in non-critically ill patients unless the BGmetric becomes one
of the inpatient care goals or part of patient care bundles. A group
of experts further delineated current problems in managing inpa-
tient diabetes and drew a roadmap to overcome the problems [18].
Each patient with diabetes admitted to the medical or surgical
ward is unique in his/her presentation. Underlying co-morbidities,
admission BG level andhemoglobinA1c, presenting complaints, out-
patient insulin use, diabetes duration, co-administration of steroids,
and nutritional status are among those variables that should inﬂu-
ence the decision-making process during evaluation for anti-
hyperglycemic therapy. All this information is objectively diﬃcult
to ascertain during the admission by internal medicine providers.
Therefore, it may still be tempting for non-endocrinologists to use
a reactive approach in the management of hyperglycemia by ini-
tiating “sliding scale” insulin regimen in spite of the evidence that
this strategy cannot only beharmful but also does not address patho-
physiology of glucose dysregulation in hospitalizeddiabetes patients.
In this review, we summarized the results of recent evidence from
the interventional trials on diabetes control in non-critically ill pa-
tients. We will discuss unique aspects of diabetes care in special
patient groups. Furthermore, we suggest potential pathways to
address both eﬃcacy and safety of diabetes treatment approaches
in the hospital.
Glycemic management of hospitalized patient with diabetes
Patients admitted to the hospital should be evaluated for a history
of diabetes, and if the diagnosis is conﬁrmed, bedside glucose moni-
toring and a therapeutic plan to manage hyperglycemia should be
initiated. Hemoglobin A1c measurement on admission will iden-
tify patients in whom optimization of outpatient diabetes treatment
is indicated. It was recently shown that, in medical and surgical non-
critically ill patients, an admission A1c >9.0% is associated with
decreased likelihood of achieving optimal inpatient glucose control
and higher insulin requirements [19]. Furthermore, an A1c >9.0%
will help identify the individuals who may beneﬁt from addition
of insulin therapy on discharge [20]. Hospitalized patients without
known history of diabetes should be strongly considered for diabetes
screening. Measurement of A1c or random BG may offer beneﬁts
in identifying new diabetes diagnosis [4] though more prospec-
tive studies needed to fully understand cost-effectiveness of universal
inpatient diabetes screening.
Patients with type 1 diabetes should be clearly identiﬁed and
promptly treated using scheduled insulin therapy. In the absence
of prospective trials in insulin-dependent diabetes patients, the start-
ing total dose of basal and bolus insulin therapy should range
between 0.3 and 0.5 units/kg/day. The 2014 inpatient diabetes na-
tional survey in the UK revealed that out of all registered diabetic
ketoacidosis cases, 7.8% developed de novo in already hospitalized
patients [21] suggesting the need for more vigilance in the care of
insulin-dependent diabetes in the hospital. In type 2 diabetes pa-
tients, we have limited options for themanagement of hyperglycemia
in the medical or surgical wards [22]. Insulin therapy is a treat-
ment of choice that addresses pathophysiology of glucoregulation.
The provision of basal insulin (BI) will target fasting hyperglyce-
mia and help to alleviate stress hyperglycemia due to insulin
resistance regardless of the patient’s nutritional state. Administra-
tion of short-acting prandial insulin in eating patients will address
abnormalities in post-prandial glucose control. For eating pa-
tients, this strategy is called a BBI regimen [13]. However, proof of
concept studies showed that for some type 2 diabetes subjects BI
plus correction insulin regimen could be another alternative in the
management of inpatient hyperglycemia [11].
The important questions in hospital practice are to identify pa-
tientswhowill beneﬁt from insulin prescription andhow to start and
tailor the insulin regimen. Prospective trials that compared eﬃcacy
of BBI therapy versus either sliding scale insulin or premixed insulin
enrolled type2diabetes subjectswithadmissionBGof 140–400mg/dL
and who had no clinical and biochemical evidence of organ failure,
receivednocorticosteroid therapy, andhadno indication for ICU trans-
fer; patientshaddifferentbaseline characteristics [7,12–14,23]. Further
analysesdemonstrate thatwhile therewere similarities in the average
admissionA1c of 8–9% andBGof 200–230mg/dL among the studies,
the end of study insulin requirementswere discordant. Average ﬁnal
total daily insulin dose was 30–40 units/day or 0.3–0.4 units/kg/day
for thosepatientswhohaddiabetesduration<10yearsandweremostly
treatedwithdiet and/ornon-insulin agents before admission [7,11,13].
In contrast, in the trials that enrolledpatientswhohad type2diabetes
for >10 years and preadmission insulin usage was recorded in >50%
of the subjects, themean effective daily insulin dose ranged between
0.5 and 0.6 units/kg/day [12,14,23,24]. The evidence guiding initial
management of diabetes in patients who are euglycemic on presen-
tation, admittedwith severe non-ketotic hyperglycemia,may require
glucocorticosteroidsand/orexhibit signsandsymptomsof organ failure
is limited.
Following the initiation of therapy, insulin titration strategies are
less well deﬁned as they were not formally tested in prospective
trials. One should keep in mind that the risks and beneﬁts of ag-
gressive BG lowering are unknown while the risk of hypoglycemia
in hospitalized non-critically ill patients is considerable and asso-
ciated with adverse clinical outcomes [25,26]. With known inter-
and intra-individual variations of pharmacokinetics and unique
mechanism of appearance in the systemic circulation of basal insulin
analogs glargine and detemir [27,28], large and frequent changes
in insulin prescription should be avoided to reduce the risk of hy-
poglycemia. As was emphasized by the Endocrine Society clinical
practice recommendations [1], insulin therapy can be increased by
10–20% if BG level is above the target; similarly, 10–20% reduc-
tion in insulin prescription should be considered if BG is below
100 mg/dL during the hospitalization.
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setting
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glucose metabolism
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Figure 1. Barriers to achieving glycemic control in non-critically ill patients with
diabetes.
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Correction insulin, a.k.a. “sliding scale insulin”, should be used
only as an adjunct therapeutic modality in hospitalized patients.
By itself, this strategy does not improve patient outcomes and can
signiﬁcantly increase risk of hypoglycemia or severe hyperglycemia
in non-critically ill setting [29–31]. When it is used as a supple-
mental insulin together with BBI or BI regimen, it can help tomanage
episodes of unexpected hyperglycemia [1]. There is no single uni-
versal formula to predict precisely the amount of correction insulin
needed [1]. Considering that patient’s total daily insulin dose and,
hence, insulin sensitivity can change during the hospitalization, a
1700 rule may allow dynamic optimization of the correction factor
to guide insulin supplementation [32].
Hypoglycemia mitigation strategies
While insulin is the most potent and proven agent to manage
diabetes in non-critically ill hospitalized patients, this therapeutic
strategy may carry signiﬁcant risk of hypoglycemia [16]. Inpatient
hypoglycemia deﬁned as BG < 70 mg/dL is associated with adverse
outcomes in diabetes patients [25,26]. There is a debate whether
hypoglycemia is a marker or cause of poor patient outcomes [15].
Until this question is resolved, we should clearly avoid and prevent
hypoglycemia in hospitalized patients. The frequency of hypogly-
cemia in inpatient diabetes in the ward can vary anywhere from
3.5% to 35% depending on the setup of the study with prospective
trials that evaluated the BBI therapy recording higher incidence likely
due to the nature of the design requiring more frequent glucose
monitoring [7,12–14,23,26,33]. One approach to reduce inpatient
hypoglycemia would be to initiate BBI regimen in insulin-naïve
patient at a dose not exceeding 0.3 units/kg/day. Alternative ther-
apeutic strategies have been recently tested in randomized controlled
studies. In patients with less pronounced admission hyperglyce-
mia, therapeutic strategies containing supplemental insulin and
either basal insulin dosed at 0.25 units/kg/day, combination of basal
insulin and a dipeptidyl peptidase-4 inhibitor sitagliptin, or sitagliptin
resulted in lower incidence of hypoglycemia at 13%, 7%, and 4%, re-
spectively [11,34]; the hypoglycemia rates were not different between
sitagliptin-based groups [34]. In one retrospective case-control study,
the authors suggested an increasing risk of hypoglycemia when pa-
tients are treated with weight-based insulin regimens above
0.4 units/kg/day [33].
In addition to the intensive glucose management, other clini-
cal factors should be strongly considered in evaluating risk of
hypoglycemia in diabetes patients. Kidney and liver failure, vari-
able caloric intake, recovery from underlying illness, mismatch
between short-acting insulin administration and meal availabili-
ty, participation in physical rehabilitation program, de-escalation
of corticosteroid therapy, and/or unrecognized adrenal insuﬃcien-
cy can all predispose to hypoglycemia. Use of intermediate action
insulin NPH as a basal insulin or inpatient prescription of pre-
mixed insulin is more likely to be associated with risk of
hypoglycemia compared with administration of insulin glargine-
based treatments [33]. In post-hoc analysis of prospective studies
conducted in non-critically ill diabetes patients, the investigators
found that hypoglycemia highly correlated with patient’s age and
renal insuﬃciency [35]. Table 1 summarizes important clinical factors
that could affect glycemic control in non-ICU diabetic patients. In
an attempt to address modiﬁable factors predisposing to hypogly-
cemia, providers should always carefully assess and monitor the
patient’s condition on a daily basis, appropriately recognize changes
in nutritional patterns and prescription of concomitant medica-
tions, use less intense insulin regimens or insulin preparations with
the lowest risk of hypoglycemia, and appropriately de-intensify
therapy when BG levels show downward trends or decrease below
100 mg/dL.
Managing hyperglycemia in special clinical populations
Previous prospective interventional trials evaluated insulin de-
livery strategies in patients with limited number of associated co-
morbid conditions, which expectedly limits the applicability of the
ﬁndings to other hospitalized patient populations. The issue with
diabetes management in special patient groups is one of the pri-
oritized topics of future inpatient diabetes research [18].
Severe non-ketotic hyperglycemia
As discussed above, inpatient hyperglycemia studies excluded
patients with admission BG >400mg/dL. Patients with acute severe
hyperglycemia will have transient decreases in insulin production
and insulin sensitivity, a phenomenon called “glucosetoxicity” [36].
To lower glycemia in a short term, intravenous delivery of insulin
and intensive rehydration should be strongly considered. In the non-
ICU setting, continuous insulin infusion could be a safe and
eﬃcacious strategy [37], but logistically very diﬃcult to imple-
ment in routine inpatient practice. In the author’s experience,
intravenous boluses of regular insulin at the dose 0.10–0.15 units/kg
every 60–120 mins accompanied by bedside glucose monitoring
could be safely and promptly done in the wards until BG is reduced
below 250–300 mg/dL. Use of “sliding scale” insulin to treat severe
hyperglycemia is not recommended due to potential insulin ab-
sorption issues in dehydrated patients with severe hyperglycemia
and insulin “stacking” phenomenon. Following the rehydration and
resolution of hyperglycemia, providers should evaluate for factors
that led to the development of severe hyperglycemia.
Steroid-induced hyperglycemia
BBI therapy is a ﬁrst choice of inpatient diabetes management
in many hospitalized patients; however, less is known about the
optimal insulin regimens to manage steroid-induced hyperglyce-
mia [1,18,38]. Steroids reduce insulin sensitivity [39], which
compellingly calls for more intensive management of the post-
prandial glucose metabolism. Recently, few studies have evaluated
the eﬃcacy of different insulin regimens in the management of
steroid-induced hyperglycemia in diabetes patients in the wards
[40–44]. These studies were different in design, patient popula-
tion, and prescription of glucocorticoid studied. Evidence suggests
that diabetes patients receiving the more potent steroid dexametha-
sonemay require insulin regimens up to 1.0–1.2 units/kg/day [40,43]
while insulin needs for the patients treated with hydrocortisone and
Table 1
Clinical factors affecting glycemic management in non-critically ill diabetes patients
1. Factors that predispose to hyperglycemia:
• Glucocorticosteroid use
• Infection
• Stress of underlying illness
• Increase in carbohydrate intake
• Parenteral nutrition
• Inadequate glycemic therapy
2. Factors that predispose to improved glucose control and/or hypoglycemia:
• Renal dysfunction
• Advanced age
• Discontinuation or reduction in glucocorticosteroids
• Decreased carbohydrate intake (NPO status, interruption of tube feeding)
• Organ failure (heart, liver, kidney)
• Adrenal insuﬃciency
• Malnutrition/frailty
• Resolution of underlying illness
• Increased physical activity/mobilization
• Polypharmacy
• Resolution of hyperglycemia (via alleviation of glucosetoxicity)
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prednisone could be lower at 0.6–0.7 units/kg/day [41,42]. In the
only prospective trial that addressed steroid-induced hyperglyce-
mia management, Grommesh et al. demonstrated that patients
required a mean total daily insulin dose of 0.4 units/kg; of note, both
diabetic and non-diabetic patients were studied in the trial [44]. Ad-
dition of a single neutral protamine Hagedorn (NPH) dose during
initiation of prednisone has been suggested [45] and recently studied
[44]; however, this approach appears to be complex. In our expe-
rience, and based on the studies that addressed the management
of dexamethasone-induced hyperglycemia, BBI regimen split as 70%
of prandial insulin and 30% of basal insulin administered as once
daily insulin glargine or twice daily insulin detemir or NPH can
provide more ﬂexibility in intensiﬁcation and then de-escalation of
insulin therapy without causing fasting hypoglycemia. More re-
search is needed to identify simple and effective insulin regimens
managing steroid-induced hyperglycemia.
Hyperglycemia in patients with renal insuﬃciency
Patients with diabetes and declining kidney function are at high
risk for hypoglycemia [46]. Decreased insulin clearance, impaired
renal gluconeogenesis, malnutrition, and hypoglycemic agents are
among the main factors predisposing to hypoglycemia in diabetic
ESRD [47–51]. Inpatient diabetes treatment studies excluded patient
with moderate to severe chronic renal insuﬃciency or acute kidney
injury. Only a few studies addressed the safety and eﬃcacy of di-
abetes management in this patient population. In hospitalized
patients with renal insuﬃciency, administration of BBI in the dose
of 0.25 units/kg/day was less likely to cause hypoglycemia and as
effective in themanagement of diabetes compared with the regimen
of 0.5 units/kg/day [52]. Therefore, based on the physiology of glucose
metabolism in patients with renal impairment and limited re-
search in the ﬁeld, initiation of BI at the dose of 0.10–0.15 units/
kg/day, if used as a monotherapy, or BBI in the dose not exceeding
0.25–0.30 units/kg/day should be considered in non-critically ill sub-
jects with renal failure including end-stage renal disease.
Hyperglycemia during enteral and parenteral nutrition
Only one prospective trial evaluated the effectiveness of differ-
ent insulin regimens in managing hyperglycemia in hospitalized
patients receiving enteral nutrition support [53]. In this study, pa-
tients with and without diabetes and BG levels >140 mg/dL were
randomized to receive either a standard therapy consisting of sliding
scale insulin or insulin glargine along with correctional insulin ad-
ministered once daily. Of note, 48% of patients in the sliding scale
group required rescue therapy with long-acting insulin due to per-
sistent hyperglycemia. Patients with diabetes required a total daily
dose of 0.61 ± 0.28 units/kg/day. The results of this investigation
suggest that starting a long-acting insulin along with correctional
short-acting insulin is an effective strategy to manage hyperglyce-
mia during enteral nutrition.
Several retrospective studies demonstrated that administration
of insulin glargine at an average dose of 34 units/day [54], insulin
NPH every 6 hours [55] or 70/30-biphasic insulin thrice daily [56]
could be used aswell for inpatient hyperglycemiamanagement. The
use of NPH may be preferable because of the shorter half-life that
facilitates its titration or discontinuation in the event tube feedings
are stopped and lower cost. Not infrequently, tube feeds could be
interrupted, which can increase the risk of hypoglycemia in these
patients receiving long-acting insulin therapy. Prompt initiation of
intravenous ﬂuids containing 10% dextrose at the rate of enteral nu-
trition therapy could reducehypoglycemia risk until enteral nutrition
is re-established [57].
Insulin is the treatment of choice to control hyperglycemia during
total parenteral nutrition (TPN). Both subcutaneous and intrave-
nous insulin have been shown to be effective in managing
hyperglycemia in these patients [58–60]. In general, adding insulin
to the TPN mixture is clinically safe and effective in controlling hy-
perglycemia. The evidence suggests that TPN insulin supplementation
at the ratio of 1 unit per 10–11 grams of carbohydrates will control
hyperglycemia in diabetes patients without signiﬁcant risk of hy-
poglycemia [59,61]. Providers should consider using weight-
based dose of basal insulin administered subcutaneously to prevent
<180mg/dL*
180 - 400 
mg/dL
>400mg/dL*
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DIET ± NON-INSULIN MEDICATIONS




-INITIATE BEDSIDE POC BG MONITORING
-CONSIDER DPP-4 INHIBITOR OR BASAL 
INSULIN 0.1 U/KG
-INITIATE BASAL INSULIN 0.15-0.2 U/KG
-ADD PRANDIAL INSULIN 0.15-0.2 U/KG IF 
EATING
-INITIATE SUPPLEMENTAL INSULIN
-INITIATE BASAL INSULIN 0.25-0.3 U/KG
-ADD PRANDIAL INSULIN 0.25-0.3 U/KG IF 
EATING
-CONSIDER INTRAVENOUS INSULIN BOLUS
-INITIATE BASAL INSULIN 0.1-0.15 U/KG
-ADD PRANDIAL INSULIN 0.1-0.15 U/KG IF 
EATING
-INITIATE SUPPLEMENTAL INSULIN
-INITIATE BASAL INSULIN 0.2-0.25 U/KG
-ADD PRANDIAL INSULIN 0.2-0.25 U/KG IF 
EATING
-INITIATE SUPPLEMENTAL INSULIN
-INITIATE BASAL INSULIN 0.25-0.3 U/KG
-ADD PRANDIAL INSULIN 0.25-0.3 U/KG IF 
EATING
-CONSIDER INTRAVENOUS INSULIN BOLUS
Figure 2. Proposed approach to initial management of hyperglycemia in non-critically ill patient with diabetes based on admission glucose level and outpatient diabetes
treatment.
POC – point of care; BG – blood glucose; DPP-4 – dipeptidyl peptidase-4.
* – non-critically ill diabetic patients admitted with these BG ranges are typically excluded from interventional studies.
† – consider continuation of home insulin regimen if compliance is conﬁrmed and there are no clinical factors that may predispose to hypoglycemia.
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fasting hyperglycemia if delivery of TPN mixed with insulin is
interrupted.
Conclusions
In non-critically ill patients, therapeutic strategies aiming to
control hyperglycemia should consider use of regimens with low
risk of hypoglycemia. Suggested hospital glycemic protocols [62,63]
are a welcome development to reduce hyperglycemia in the hos-
pitalized patients, but these insulin regimens may not take into
account heterogeneity of the diabetes phenotypes in the hospital
wards, which can pose a risk of hypoglycemia if these protocols are
universally used. In fact, eﬃcacy and safety of different initial insulin-
containing regimens have not been tested in head to head trials so
providers are left alone in selecting the best insulin regimen to treat
hyperglycemia and, often, they choose the path of least resistance
and initiate “sliding scale” insulin as therapy of choice. As it oc-
curred with the outpatient diabetes management strategies, we
should shift from “one size ﬁts all” approach to more patient-
centered treatment strategies that take into account the patient’s
co-morbidities, risk of hypoglycemia, duration of diabetes, and use
of medications that affect insulin-resistance. Fig. 2 presents an ap-
proach that combines existing clinical evidence and patient-
centered considerations in selecting safe and effective regimens to
control diabetes in non-critically ill patients.
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